BeiGene

BeOne Medicines, formerly BeiGene, is a multinational oncology company dedicated to developing innovative drugs for cancer treatment. Employing a science-led, purpose-driven model, the company discovers and advances impactful medicines. Its comprehensive pipeline targets various solid tumors and hematological malignancies, aiming to bring therapies to patients globally.

The company was co-founded on October 28, 2010, by entrepreneur John Vincent Oyler and biochemist Xiaodong Wang. Their shared vision arose from a determination to establish a global biopharmaceutical enterprise rooted in China, committed to developing affordable, effective cancer therapies. Oyler’s business acumen and Wang’s scientific expertise provided the foundational insight for its inception.

BeOne Medicines serves cancer patients globally. Its long-term vision is to significantly advance worldwide cancer care through the accelerated delivery of transformative medicines. The company strives to expand treatment access to a broader patient population, ensuring more individuals benefit from its scientific advancements in the fight against the disease.